{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:02:23Z","timestamp":1794852143510,"version":"4.9.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.drugalcdep.2008.07.018","type":"journal-article","created":{"date-parts":[[2008,9,26]],"date-time":"2008-09-26T08:51:29Z","timestamp":1222419089000},"page":"345-349","source":"Crossref","is-referenced-by-count":208,"title":["Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty"],"prefix":"10.1016","volume":"99","author":[{"given":"Tami L.","family":"Mark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl A.","family":"Kassed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Vandivort-Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine R.","family":"Levit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry R.","family":"Kranzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2008.07.018_bib1","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1172\/JCI29999","article-title":"Drug discovery in jeopardy","volume":"116","author":"Cuatrecasas","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drugalcdep.2008.07.018_bib2","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMp078020","article-title":"The demise of the blockbuster?","volume":"356","author":"Cutler","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.drugalcdep.2008.07.018_bib3","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/01.jcp.0000246209.18777.14","article-title":"Trends in the adoption of medications for alcohol dependence","volume":"26","author":"Ducharme","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2008.07.018_bib4","unstructured":"Gilbert, J., Henske, P., Singh, A., 2003. Rebuilding Big Pharma\u2019s Business Model. IN VIVO: The Business and Medicine Report. Available at http:\/\/bain.com\/bainweb\/PDFs\/cms\/Public\/rebuilding_big_pharma.pdf [accessed on May 14, 2008]."},{"key":"10.1016\/j.drugalcdep.2008.07.018_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.drugalcdep.2004.02.004","article-title":"The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991\u20131992 and 2001\u20132002","volume":"74","author":"Grant","year":"2004","journal-title":"Drug. Alcohol. Depend."},{"key":"10.1016\/j.drugalcdep.2008.07.018_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jsat.2007.02.004","article-title":"Availability of addiction medications in private health plans","volume":"34","author":"Horgan","year":"2008","journal-title":"J. Subst Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2008.07.018_bib7","unstructured":"IMS, 2007. Commonly Requested Therapeutic Class and Product Information. http:\/\/imshealth.com\/ims\/portal\/front\/articleC\/027776599_18731_63237611,00.html [accessed on May 14, 2008]."},{"key":"10.1016\/j.drugalcdep.2008.07.018_bib8","unstructured":"IMS National Prescription Audit Plus\u2122, 2005. Promotional brochure and documentation. IMS, Plymouth Meeting, PA."},{"key":"10.1016\/j.drugalcdep.2008.07.018_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bcp.2007.08.005","article-title":"Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings","volume":"75","author":"Johnson","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2008.07.018_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.57.1.1","article-title":"Pharmacogenetics and human molecular genetics of opioid and cocaine addictions and their treatments","volume":"57","author":"Kreek","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.drugalcdep.2008.07.018_bib11","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrd897","article-title":"Pharmacotherapy of addictions","volume":"1","author":"Kreek","year":"2002","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.drugalcdep.2008.07.018_bib12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1517\/14728214.10.2.323","article-title":"Development of medications for alcohol use disorders: recent advances and ongoing challenges","volume":"10","author":"Litten","year":"2005","journal-title":"Expert. Opin. Emerg. Drugs."},{"key":"10.1016\/j.drugalcdep.2008.07.018_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF02287829","article-title":"Access to new medications to treat schizophrenia","volume":"29","author":"Mark","year":"2002","journal-title":"J. Behav. Health Serv. Res."},{"key":"10.1016\/j.drugalcdep.2008.07.018_bib14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0376-8716(03)00134-0","article-title":"Understanding U.S. addiction physicians\u2019 low rate of naltrexone prescription","volume":"71","author":"Mark","year":"2003","journal-title":"Drug. Alcohol. Depend."},{"key":"10.1016\/j.drugalcdep.2008.07.018_bib15","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1176\/appi.ajp.162.8.1423","article-title":"Anticraving medications for relapse prevention: a possible new class of psychoactive medications","volume":"162","author":"O\u2019Brien","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2008.07.018_bib16","first-page":"153","article-title":"Psychotherapy and pharmacotherapy in depression","volume":"5","author":"Powers","year":"2002","journal-title":"J. Ment. Health Policy Econ."},{"key":"10.1016\/j.drugalcdep.2008.07.018_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.18553\/jmcp.2006.12.1.43","article-title":"Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims","volume":"12","author":"Robinson","year":"2006","journal-title":"J. Manage. Care Pharm."},{"key":"10.1016\/j.drugalcdep.2008.07.018_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0740-5472(02)00319-7","article-title":"Research to practice: adoption of naltrexone in alcoholism treatment","volume":"24","author":"Thomas","year":"2003","journal-title":"J. Subst. Abuse Treat."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871608003050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871608003050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T04:35:08Z","timestamp":1631853308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871608003050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":18,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0376871608003050"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2008.07.018","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}